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A positive exercise electrocardiogram (ECG) has been 
proved to predict cardiovascular events in asymptomatic 
normolipidemic men. To study whether it is also predictive 
for hypercholesterolemic men, data from 3,806 asympto- 
matic hypercbolesterolemic men in the Lipid Research 
Clinics Coronary Primary Prevention Trial were analyzed. 
All the men had performed a submaximal treadmill exer- 
cise test at baseline, before they were assigned to the 
cholestyramine or placebo treatment group. Because of 
missing or inconclusive data, 31 men were excluded from 
the analyses. A test was positive if the ST segment was 
displaced by ~1 mm (visual code) or there was 210 pV-s 
change in the ST integral (computer code), or both. The 
prevalence of a positive test was 8.3%. 
During the 7 to 10 year (mean 7.4) follow-up period, the 
mortality rate from coronary heart disease was 6.7% (21 of 
315) in men with a positive test and 1.3% (46 of 3,460) in 
men with a negative test (placebo and cholestyramine 
groups combined). The age-adjusted rate ratio for a posi- 
tive test, compared with a negative test, was 6.7 in the 
placebo group and 4.8 in the cholestyramine group. With 
use of Cox’s proportional hazards models, it was found that 
the risk of death from coronary heart disease associated 
with a positive test was 5.7 times higher in the placebo 
group and 4.9 times higher in the cholestyramine group 
after adjustment for age, smoking history, systolic blood 
pressure, high density lipoprotein cholesterol and low den- 
sity lipoprotein cholesterol. A positive test was not signifi- 
cantly associated with nonfatal myocardial infarction. 
Thus, the results indicate that the exercise ECG re- 
sponse is a valuable and independent predictor of the risk of 
death from coronary heart disease in hypercholesterolemic 
men. 
{J Am Co11 Cardiol1989;14:55&63) 
A positive exercise electrocardiogram (ECG) has been 
proved to predict cardiovascular events in both symptomatic 
patients with known coronary artery disease (l-6) and 
asymptomatic persons without clinical evidence of coronary 
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artery disease (7-18). Bruce et al. (15,16) noted that a 
positive test in healthy asymptomatic men was predictive 
only in persons with another risk factor, such as smoking or 
high plasma cholesterol. However, data from the Lipid 
Research Clinics Prevalence Follow-up Study (18) showed 
the exercise ECG response to bc predictive independent of 
other risk factors. 
This report presents data from the Lipid Research Clinics 
Coronary Primary Prevention Trial. The participants in this 
trial are a unique group of patients, selected on the basis of 
having a single important risk factor, namely, elevated 
plasma cholesterol or low density lipoprotein (LDL) choles- 
terol, but who were otherwise healthy. The design of the 
study (19) and the results of the intervention with choles- 
tyramine (20) have been published previously. In contrast, 
the predictive value of an exercise ECG has not been studied 
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in these patients nor in any group of patients with similar 
characteristics. 
The aim of the present study was to investigate whether 
the exercise ECG response measured at baseline before 
randomization is associated with death from coronary heart 
disease and nonfatal myocardial infarction. 
Methods 
Study subjects. Details regarding the design, implemen- 
tation and major results of the Coronary Primary Prevention 
Trial have been reported previously (19,20). Briefly, it was a 
double-blind, placebo-controlled clinical trial that tested the 
efficacy of lowering cholesterol levels with cholestyramine 
for the primary prevention of coronary heart disease. 
Twelve Lipid Research Clinics recruited 3,806 men, 35 to 59 
years old. with primary hypercholesterolemia, who were 
free of symptomatic coronary heart disease at entry. At 
entry, participants had to have a plasma total cholesterol of 
2265 mg/dl and plasma LDL cholesterol of 2175 mgidl or 
greater. lMen with a plasma triglyceride level >300 mg/dl or 
with type III hyperlipidemia were excluded. 
Potential participants also were excluded from the triul if 
they had any signs of clinically manifest coronary heart 
disease based on history, ECG at rest or physical examina- 
tion. Men were also excluded if they had secondary hyper- 
lipoproteinemia, were overweight (body mass index >32.l 
kg/m*), had hypertension (?165/105 mm Hg), were receiving 
antihypertensive medication or other cardiovascular medi- 
cation or had diabetes. Men with a positive exercise test in 
the absence of other manifestations of coronary heart dis- 
ease were not excluded from the trial. 
Participants were randomized into II treatment group that 
received cholestyramine and a control group that received a 
placebo. The primary end point for evaluating the treatment 
outcome in the Coronary Primary Prevention Trial was 
death from coronary heart disease or nonfatal myocardial 
infarction, or both, during a follow-up period of 7 to 10 
years. All participants initially entered were followed up 
until completion of the trial. 
Exercise tolerance test. A standardized submaximal 
treadmill test adapted from the Bruce protocol was used 
(21.22). Participants were requested to abstain from food, 
coffee and tobacco for at least 2 h before testing. The test 
consisted of up to seven stages, each of 3 min duration, 
followed by a 6 min period of postexercise observation. 
Before the test began, a target heart rate for each man was 
defined as 90% of the average maximal heart rate attained by 
healthy men of comparable age and physical condition (22). 
Heart rate was monitored by ECG during exercise. When 
the target heart rate was I) reached at the end of a stage. 2) 
sustained for at least I min, or 3) exceeded by IO beats/min, 
the test was terminated. The test could be terminated before 
attainment of the target heart rate because of the partici- 
pant’s inability to continue as a result of advanced fatigue, 
dyspnea or leg pain (a symptom-limited test) or because of 
safety considerations (such as ECG changes, angina pectoris 
or a decrease in systolic blood pressure), technical diffi- 
culties or noncooperation. 
Exercise ECG response. The response was classified as 
positive or nonpositive for ischemia at the ECG coding 
center in Birmingham, Alabama, which applied uniform 
criteria for all tests performed in the Coronary Primary 
Prevention Trial. The coding center received electromag- 
netic tapes of each exercise test, containing continuous ECG 
recordings in the precordial (VI,VS,Vh) and Frank (X,Y,Z) 
leads, from which tracings of representative portions were 
generated. Each test was coded both by certified techni- 
cians, who examined the degree of ST depression (or eleva- 
tion) at 0.08 s after the .I point, and by a computer program, 
which calculated the ST integral (23). In most cases. the 
visual and computer codes were in agreement (24). Discrep- 
ancies were evaluated by a supervisor, and erroneous codes 
were corrected or deleted. 
A test ~‘as considered to he positive if I) an additional ST 
depression or elevation of 2 I mm was recorded by the visual 
coders; 2) the ST integral decreased by -zlO pV-s from its 
value at rest or to a value of -IO pV-s if the ST level at rest 
wad positive; or 3) the ST integral increased by 210 PV-s 
from its value at rest. 
Because a greater ST response or one that occurs at a 
lower work load is likely to be indicative of more severe 
impairment of the myocardial circulation (4,5,25,26), posi- 
tive tests were further subdivided according to the degree of 
ST depression (or elevation) and by how early in the test it 
was observed. A positive test in which the ST response was 
22 mm or -20 pV-s or occurred during the first 6 min of the 
exercise test, or at a heart rate 5163 - 0.66 X age, was 
considered strongly positive (27). The remaining positive 
tests were classified as weakly positive tests. The tests that 
did not fulfill these ST criteria were called negative. Initially, 
they were divided into clearly negative and inconclusive 
tests on the basis of whether the participant had also 
developed some cardiovascular symptoms or did not reach a 
maximal target heart rate minus 30 beatsimin. However. the 
clearly negative and inconclusive tests behaved similarly in 
the preliminary analyses and, thus, were grouped together to 
simplify the presentation. Men with minor Q waves and 
minor T wave abnormalities were not excluded from the 
analyses because those changes do not interfere with the 
sensitivity or specificity of the exercise ECG (26). 
Risk factor measurements. Plasma lipid. lipoprotein and 
glucose levels were measured in men who had fasted 2 I2 h 
(28). Low density lipoprotein cholesterol levels were deter- 
mined ultracentrifugally. Information on smoking history, 
alcohol consumption, medications and reported physical 
activity was obtained by questionnaire (29). The presence of 
angina was evaluated by the Rose questionnaire (29). Height 
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and weight were measured with the participant wearing light 
clothing but no shoes. Body mass index was calculated by 
dividing weight (in kilograms) by the square of height (in 
meters). Blood pressure was measured after the participant 
had been in a sitting position for 5 min; the mean value of the 
two random zero measurements was used. 
Dichotomous class&ations (coded 1 or 0) were con- 
structed for blood pressure (systolic blood pressure >140 
mm Hg, diastolic blood pressure >90 mm Hg), plasma 
glucose > 115 mg!dl, presence of parental history of myocar- 
dial infarction or angina before 60 years of age and reported 
strenuous physical activity (yes or no). 
Statistical methods. In this study, separate analyses were 
performed for the placebo and cholestyramine groups be- 
cause cholestyramine treatment has been shown (20) to 
modify the underlying hazard of coronary heart disease. We 
first present the age-adjusted incidence rates of the following 
events in men with each of the three possible ECG outcomes 
in response to exercise at baseline: total deaths. deaths due 
to coronary heart disease and definite nonfatal myocardial 
infarction. The direct method of standardization is used to 
compute age-adjusted rates. The person-years value com- 
bined for both treatment groups for all ECG outcomes is 
considered as the standard reference group. If the event is a 
nonfatal myocardial infarction, the person-years value of 
exposure for those who experience the event in each age 
interval is computed as the time to occurrence of the first 
myocardial infarction in the interval. After the occurrence of 
the first myocardial infarction, the individual is treated as a 
censored observation. Similarly, in case of the combined 
coronary event of death due to coronary heart disease or 
nonfatal myocardial infarction, the time to occurrence of the 
event that occurred first is counted toward the person-years. 
After the first event, the man is treated as censored (for 
example, if nonfatal myocardial infarction occurred first, the 
time to occurrence to myocardial infarction is counted and 
the observation is treated as censored, regardless of whether 
the man subsequently died from coronary heart disease). 
Proportional hazards models (30,31) were used to test the 
predictive value qfthe exercise test, controlling for a number 
of confounding variables. In addition to the ECG outcome 
variables, the model included age, LDL cholesterol, high 
density lipoprotein (HDL) cholesterol, systolic blood pres- 
sure, alcohol (g/day), smoking status and family history 
(whether or not either of his parents had experienced myo- 
cardial infarction or angina before 60 years of age). In some 
models, the ECG outcome is coded as “positive” or “neg- 
ative,” whereas in selected models, the “positive” outcome 
variable is further divided as “strongly positive” or “weakly 
positive.” 
i& estimated relative risk of the occurrence of the event 
for a positive ECG outcome, compared n:itjz a negative ECG 
outcome, was computed as the antilog of the estimated co- 
efficient corresponding to the dichotomous outcome vari- 
Table 1. Frequency of Categorically Defined Baseline Covariates. 
by Treatment Group 
Placebo Cholestyramine 
(n = 1,884) (a = 1,891) 
Variable (%) (%) 
Minor Q. T wave changes 2.5 1.8 
Family history CHD 24. I 24.2 
Smoker 36.7 38.3 
Physically active 30.3 31.1 
Hypertensive* 16.0 16.2 
Glucose 115 to 130 mg/dl+ 3.4 4.0 
*Men with blood pressure between 140/W and 1651105 mm Hg; tMen with 
glucose 2130 mgidl were excluded from the Coronary Primary Prevention 
Trial. CHD = coronary heart disease. 
able. When the ECG outcome is coded in a three-way 
category (strongly positive, weakly positive or negative), 
risks relative to negative ECG outcomes were computed and 
interpreted in the same manner. Upper and lower limits for 
95% confidence intervals for the increased risk associated 
with a positive ECG outcome were calculated from the es- 
timated coefficient for a positive exercise test, p, and its 
standard error, SE, by the approximation ep * ‘.% SE. 
Using the proportional haznrds models for each ECG 
outcome, we separately computed survival curves depicting 
the probability of not experiencing the event by duration of 
follow-up. For this purpose, the value of each of the contin- 
uous variables was set at their mean level. Dichotomous 
variables (such as smoking or family history) were set to 
zero. For convenience of presentation. we present the cu- 
mulative percent experiencing each event by duration of 
follow-up. These cumulative percents were calculated as the 
complement of the estimated survival probability (that is, 
[I - estimated survival probability]). 
Results 
Study group. From the total original Coronary Primary 
Prevention Trial study group, we excluded 10 men from the 
placebo group and 12 from the cholestyramine group from 
our analyses because of missing data. In addition, five from 
the placebo and four from the cholestyramine group were 
excluded because of clinical signs of coronary heart disease 
at baseline study. In those excluded, one death and one 
nonfatal myocardial infarction occurred. The remaining 
study groups consisted of 1,884 men in the placebo group 
and 1,891 men in the cholestyramine group. Baseline char- 
acteristics are shown for dichotomous risk factors in Table 1, 
and for continuous risk factors in Table 2. In terms of these 
variables, there were no statistically significant differences at 
baseline study between the two treatment groups. 
Exercise test results. The prevalence of a positive ECG 
outcome was 8.3% (315 of 3,775), 36% of the positive tests 
being strongly positive. Only six tests were positive as a 
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Table 2. Mean Values and Standard Errors of Baseline &variates, by Treatment Group 
Variable NO. 
Placeh” Group 
Meall SE 
Cholestyramine Group 
NO. Mean s; 
Age (~0 I ,X84 41.6 0.2 I.891 47.3 0.1 
LDI, (mg/dll I.884 2lb.2 0.8 I.891 215.6 0.7 
HDL (mgidl) I ,X84 45 n.2 I.891 45 0.2 
Triglyceride (mgidl) 1,884 158.2 1.4 I.891 159.7 I .4 
Systolic BP (mm Hg) 1,873 120.6 0.3 1.878 120.8 0.3 
Diastohc BP (mm Hg) I.873 79.7 0.2 1.878 79.8 0.2 
Alcohol (giddy) I.869 I6 0.5 1.866 15.6 0.4 
BMI (kg/m’) I ,87X 2f5.c 0. I I.888 26.4 0.1 
AM1 = hody mass index: BP = blood pressure: HDL = high density lipoprotein cholesterol: LDL = low density 
lipoprotein cholesterol: SE = standard error 
result of ST elevation. Approximately 81% of the men 
terminated the exercise test because they reached their 
target heart rate, approximately 16% because of advanced 
fatigue and approximately 3% because of other symptoms. 
Table 3 presents the exercise ECG outcome and the crude 
coronary heart disease mortality and morbidity rates in the 
different ECG outcome categories. 
Mortality and coronary events. For all-cause mortality, 
deaths attributed to coronary heart disease and nonfatal 
myocardial infarction, a higher proportion of events devel- 
oped in men with a positive rather than a negative ECG 
outcome. In all but one instance shown in Table 3. a gradient 
in the percent cumulative events can be seen according to 
ECG outcome: highest in strongly positive, intermediate in 
weakly positive and lowest in negative. 
Given the differences in follo~wp period, age-adjusted 
rates per 1,000 person-years are more meaningful than 
cumulative mortulity rates. Table 4 presents rates per 1,000 
person-years for the four study end points, and shows that in 
the placebo group (but not the cholestyramine group), the 
incidence of nonfatal myocardial infarction was higher (by 
40%) in the positive ECG outcome group than in the negative 
group. In contrast, the age-adjusted rates of either death 
from coronary heart disease or all-cause mortality were 
consistently and markedly higher among the men with a 
positive ECG outcome than among men with a negative 
ECG outcome in both randomized treatment groups. Risk 
ratios ranged from 3.2 to 6.7. 
Comparison of positive exercise test with other risk factors 
in both treatment groups. We tested the independence of a 
positive exercise test to predict death from coronary heart 
disease from that of the known major risk factors by includ- 
ing them in a proportional hazard model for each outcome. 
The variables included in the models were age, LDL choles- 
terol, HDL cholesterol, systolic blood pressure at rest, 
smoking history, alcohol use and family history of coronary 
heart disease. Only significant variables for each outcome 
are used in the tables. Plasma triglyceride, plasma glucose 
> 115 mg/dl, physical activity, hematocrit and white blood 
cell count were also considered (Tables 5 and 6). 
A positive test remained a statistically significant predic- 
tor for death due to coronary heart disease even after 
adjustment for the other risk factors-LDL cholesterol and 
smoking history being the most important. The estimated 
relative risk associated with a positive ECG outcome 
changed very little compared with the unadjusted estimates. 
Table 3. Number and Percent of Coronary Events by Exercise Test Outcome and by 
Treatment tiroup 
Death 
Exercise Test No. of 
(all causes1 
Outcome Patienls n ‘X 
Placebo group 
Strongly positwe 50 8 16.0 
Weakly positive IO4 8 7.7 
Negative 1.730 54 3.1 
Cholestyramine group 
Strongly positive 63 9 14.3 
Weakly positive 98 6 6.1 
Negative 1.730 53 3.1 
CHD = coronary heart disease; MI = myocardial infarction. 
CHD Deaths 
” 5x 
6 12.0 
5 4.8 
26 I.5 
6 9.5 
4 4.1 
20 1.2 
Nonfatal MI 
n % 
5 10.0 
II 10.6 
I41 8.2 
6 9.5 
6 6.1 
II8 6.8 
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Table 4. Age-Adjusted Rates per 1,000 Person-Years, by Treatment Group and Outcome of 
Exercise Test 
Exercise Placebo 
Test 
End Point Outcome Rate SE 
All-CiiUSC Positive 16.2 4.8 
mortality Negative 4.1 0.6 
Definite Positive 13.0 4.6 
CHD death Negative I.9 0.4 
Nonfatal Ml Positive 15. I 4.7 
Negative 10.9 0.9 
RR = rtsk ratio; other abbrewations as in Tables 2 and 3. 
RR 
4.0 
1.0 
6.7 
1.0 
1.4 
1.0 
Cholestyramme 
Rate SE RR 
12.8 3.8 3.2 
4.0 0.5 1.0 
7.2 2.3 4.8 
I.5 0.3 I .o 
9.4 2.8 1.0 
9. I 0.8 I.0 
A positive test was associated with 5.7-fold and 4.9-fold 
increases in death from coronary heart disease in the placebo 
and cholestyramine groups, respectively. If a man had a 
strongly positive test, the relative risk for death from coro- 
nary heart disease was markedly increased, by a factor of 
10.3 and 6.3 in the placebo and cholestyramine groups, 
respectively (Tables 5 and 6, Fig. I). Note that coronary 
heart disease occurred very early during the follow-up 
period in men with a strongly positive exercise test. 
A positive test was not associated to a statistically 
significant degree with nonfatal myocardial infarction in 
either treatment group. The corresponding relative risk was 
1.2 in both groups, with confidence intervals of 0.7 to 2. I in 
the placebo group and 0.6 to 2.1 in the cholestyramine group 
(Tables 5 and 6). In contrast, a positive test was strongly and 
significantly (p < 0.0001) associated with all-cause mortality 
with relative risks of 3.3 and 2.9 for a positive test, compared 
with a negative test, in the placebo and cholestyramine 
groups, respectively. 
Discussion 
Prevalence of a positive exercise test. The prevalence of a 
positive ECG response in the Coronary Primary Prevention 
Table 5. Relative Risk* (and 95% confidence interval) of 
All-Cause Mortality, Death From Coronary Heart Disease and 
Nonfatal Myocardial Infarction by Electrocardiographic Response 
to Exercise in the Placebo Group 
ECG Response 
Any Weakly Strongly 
End Pomts Negative Positive Positive Positive 
All-cause mortality I.0 3.3 2.4 5.4 
(1.8, 5.9) (1.1, 5.2) (2.5. 11.8) 
Definite CHD death 1.0 5.1 3.9 IO.3 
(2.7. 12.2) (1.4. IO.31 (3 9, 27 I) 
Nonfatal MI 1.0 1.2 1.3 I.1 
(0.7, 2.1) (0.7. 2.4) (0.4, 2.7) 
*Hazard ratio computed ftom proportional harat-d models, that included 
age, low density lipoprotein cholesterol. high density lipoprotein cholesterol. 
systolic blood preswre. smoking slatus, family history and elecrrocardio- 
graphic (ECG) outcome. Values in parentheses are 95% confidence limits for 
relative risk. Abbreviations as in Table 3. 
Trial was 8.3%, which is higher than the 5.1% found in the 
Lipid Research Clinics Prevalence Follow-up Study patients 
(l8), as assessed by exactly the same technique. The higher 
prevalence is explained by the fact that the Coronary Pri- 
mary Prevention Trial population is a high risk population 
with a high prevalence of subclinical coronary artery disease 
(32). even though the men were selected as being asympto- 
matic. The Lipid Research Clinics Follow-up Study patients, 
on the other hand, were a population-based sample. 
In another high risk population, the Multiple Risk Factor 
Intervention Trial (MRFIT) (33), the prevalence of a positive 
exercise response was higher (12.2%). Their treadmill pro- 
tocol was similar to that used in the Coronary Primary 
Prevention Trial, with a target heart rate termination. How- 
ever, the ECG lead groups differed, the main difference 
being the use of lead CS, in the MRFIT trial, which detected 
most of the positive cases. Different computer programs and 
a different definition of a positive response were used in the 
two trials. 
“False positive” vs. “false negative” tests. The 271 men 
in our study with a positive test, but without a subsequent 
event due lo coronary heart disease, might conventionally be 
considered to have had a false positive result. However, as 
mentioned before, men with known coronary heart disease 
could be expected to live longer than the 7.4 year mean 
Table 6. Relative Risk (and 95% confidence interval) of All-Cause 
Mortality, Death From Coronary Heart Disease and Nonfatal 
Myocardial Infarction by Electrocardiographic Response to 
Exercise in the Cholestyramine Group 
ECG Response 
Any Weakly Strongly 
End Pomts Negative Positive Positive Positive 
All-cause mortality 1.0 2.9 2.1 3.8 
(1.6, 5.2) (0.9, 4.9) (1.9. 7.9) 
Definite CHD death I .o 4.9 3.6 6.3 
(2.2. 10.8) (I.?, 11.0) (2.5, 16.3) 
Nonfatal MI 1.0 1.2 1.0 I.4 
(0.6, 2.1) (0.4, 2.2) (0.6, 3.3) 
Abbreviations and definitions as in Table 5. Values in parenthesis are 95% 
confidence limits for relative risk. 
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Figure 1. Cumulative percent of death from 
coronary heart disease in men with strong, 
weak and negative exercise test (ETT) in the 
placebo (upper) and cholestyramine groups 
(lower). Life table failure plots are computed 
from proportional hazards mod& that include 
age, low density lipoprotein cholesterol. high 
densiry lipoprotein cholesterol. systolic blood 
pressure. smoking status, family history of cor- 
onary heart disease and exercise test outcome. 
The number of subjects at risk at follow-up 
years 2, 4. 0 and 8. respectively. were 1,864. 
1,853. 1,834 and 622 in the placebo group and 
1,883. 1,869, 1,851 and 618 In the choles- 
tyramine group. 
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duration of the follow-up study. and some could be expected 
to die of other causes. Among the men with a negative test, 
296 (8.6%) had an event due to coronary heart disease and 
might conventionally be considered as having false negative 
results. However, the exercise test was performed at the 
baseline of a prolonged follow-up period and many of those 
with a “false negative” result could have developed signif- 
icant coronary artery disease after being tested. As reported 
in the final results of the Coronary Primary Prevention Trial 
(20). 605 men developed a positive exercise ECG response 
during the follow-up period. Using coronary arteriography 
as a reference standard-thereby eliminating the time fac- 
tor-many studies (l-5) have reported relatively high figures 
for false positive and false negative exercise tests. Because 
the exercise ECG measures the functional capacity of the 
coronary circulation and coronary arteriography measures 
the anatomic capacity, a discordance between the physio- 
logic assessment and the anatomic assessment is not implau- 
sible (34). 
Predictive value of a positive exercise test. In the placebo 
group, the sensitivity, specificity and positive predictive 
value with respect to death due to coronary heart disease 
were, respectively, 29.7%, 92.3% and 7.1% for any positive 
test, and 16.2%. 97.6% and 12.0% for a strong positive test. 
The\e results were very similar in the cholestyramine group. 
A positive exercise ECG response wa5 a powerful pre- 
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dictor of death from coronary heart disease in the Coronary 
Primary Prevention Trial. The rate ratio for death associated 
with a positive test was 5.7 in the placebo group and 4.9 in 
the cholestyramine group, after adjustment for other risk 
factors (Table 5). These adjusted rate ratios are almost 
identical to the ratios of age-adjusted rates for death due to 
coronary heart disease per 1,000 person-years (6.7 and 4.8 in 
the placebo and cholestyramine group, respectively), indi- 
cating that the risk was independent of risk factors other 
than age. These rate ratios are similar to the 4.6 ratio re- 
ported from the Lipid Research Clinics Prevalence Follow- 
up Study (IQ, but somewhat higher than the 3.8 ratio 
observed in the MRFIT trial (33). The increased risk asso- 
ciated with a positive test was particularly marked when this 
response occurred in the first two stages of exercise. at a low 
heart rate or when ST depression exceeded 2 mm or 20 WV-S. 
which we called a strongly positive test. Age-adjusted mor- 
tality rates due to coronary heart disease were approxi- 
mately two to three times higher in men with a strongly 
positive test compared with a weakly positive test (Table 6). 
These findings are in general agreement with those for the 
hyperlipidemic patients in the Lipid Research Clinics Fol- 
low-up Study (18) and with other studies (25.33) reporting 
the predictive value of 2 mm of ST depression or depression 
occurring below 85% of the predicted maximal heart rate. In 
contrast, neither a weakly nor a strongly positive exercise 
ECG response was predictive of future nonfatal myocardial 
infarction. This is in agreement with the Multiple Risk 
Factor Intervention Trial (33), which reported a nonsignifi- 
cant relative risk of I .04 and I .25 for nonfatal myocardial 
infarction. 
Coronary disease death versus nonfatal infarction. There 
is no simple explanation for the difference between death 
due to coronary heart disease and nonfatal myocardial in- 
farction and their relation to the exercise ECG response. 
One possible explanation is that a positive exercise ECG is a 
marker of a subgroup of subjects with coronary heart disease 
more likely to die suddenly of an arrhythmia related to an 
infarction. The participants developing nonfatal myocardial 
infarction may have a less severe form of coronary heart 
disease, with different patterns of risk factors and different 
factors triggering a nonfatal event. Many patients with clear 
evidence of coronary heart disease have a very good prog- 
nosis, especially if they bring about a change in their risk 
factors by such means as stopping smoking or controlling 
blood pressure or lipid levels. or both. That would be es- 
pecially true for participants developing angina pectoris and, 
therefore, seeking medical care, resulting in drug treatment 
and a change in lifestyle. In the Coronary Primary Preven- 
tion Trial, a positive exercise ECG outcome (silent ischemia) 
was strongly associated with the development of new cases 
of angina pectoria (35). 
Cholestyramine group versus placebo group. The hazard 
ratios for both a weak positive test and for a strong positive 
test are smaller in the cholestyramine group than in the 
placebo group (Tables 5 and 6). These differences are 
suggestive (Fig. I), but are not statistically significant, pos- 
sibly because of the small number of deaths observed in each 
group. However, the MRFIT trial reported that in the group 
with an abnormal exercise test, the mortality rate from 
coronary heart disease was significantly lower in the special 
intervention group compared with the usual care group (36). 
Conclusions. Our results show that an ischemic ECG 
response to exercise is a powerful predictor of death from 
coronary heart disease in hypercholesterolemic middle-aged 
men independent of other risk factors. This association was 
present in both treatment groups (cholestyramine and pla- 
cebo) of the Lipid Research Clinics Coronary Primary Pre- 
vention Trial. The lack of an association between a positive 
exercise ECC response and the occurrence of nonfatal 
coronary heart disease represents an intriguing-previously 
reported (35,36)-finding. 
The computations for the manuscript were done by Larry Wallman, Larry 
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